unclear. GH therapy has been suggested to decrease TSH by both a direct central and an indirect peripheral mechanism. Analysis of T3 levels is required to distinguish between these hypotheses and elucidate whether Thyroxine supplementation would be of benefit. Background and Aim: Henoch-Schönlein Purpura (HSP) is one of the commonest forms of systemic small vessel vasculitis in children, and kidney involvement is frequent. Current pathology classification systems have not proved useful in determining long-term kidney outcomes in children with HSP nephritis. The aim of this study was to determine if the Oxford IgA MEST score is associated with long-term outcomes in childhood onset HSP.
unclear. GH therapy has been suggested to decrease TSH by both a direct central and an indirect peripheral mechanism. Analysis of T3 levels is required to distinguish between these hypotheses and elucidate whether Thyroxine supplementation would be of benefit. Background and Aim: Henoch-Schönlein Purpura (HSP) is one of the commonest forms of systemic small vessel vasculitis in children, and kidney involvement is frequent. Current pathology classification systems have not proved useful in determining long-term kidney outcomes in children with HSP nephritis. The aim of this study was to determine if the Oxford IgA MEST score is associated with long-term outcomes in childhood onset HSP.
SOUTH
Method: This was a single-centre, retrospective cohort study of children 0 to 18 years with HSP nephritis between 2002 and 2016. Renal biopsies were scored based on the MEST criteria, (M=mesangial hypercellularity, E=endocapillary hypercellularity, S=segmental glomerulosclerosis, T=tubular atrophy/interstitial fibrosis) and the presence of crescents and C3 deposition. Analyzed by logistic regression, we determined if biopsy scores were associated with a composite outcome of proteinuria (protein:creatinine ratio >20mmol/mmol) and/or eGFR <90ml/min/1.73m 2 ,
controlling for age at presentation and sex. Results: We identified 47 children (F=62.7%) with biopsies, followed for at least 6 months. At presentation, median age was 9.5yrs (IQR 5.9 -14.1). Median length of follow-up was 2.5yrs (IQR 1.5 -5). Pathology review determined 36.2% had a combined MEST score ≥3, 63.8% had crescents and 61.7% had C3 staining >1+. There were 76.6% treated with steroids and 44.7% with an ACE inhibitor /angiotensin II receptor blocker. A MEST score ≥3 had an adjusted odds of 8.0 [95% CI 1.4 to 46.9] and the presence of crescents gave an adjusted odds of 5.1 [95% CI 1.1-22.8] of reaching the composite outcome. C3 was not significantly associated with the composite outcome with adjusted odds of 1.8 [95% CI 0.5-6.9].
Conclusions: MEST pathological score of ≥3 and presence of crescents in children with HSP nephritis is associated with a worse outcome by 2.5 years. This study suggests that pathological classification might be useful for disease prognosis, perhaps identifying a group at risk of CKD progression. Background: Behavioural sleep problems are common and highly amenable to parent-led treatment. However, many children are referred to Royal Children's Hospital (RCH) Sleep Clinic with such problems, contributing to an 8-month long waitlist.
Aims: Determine the feasibility and acceptability of tailored behavioural sleep management advice versus general advice, delivered to parents of children on a sleep clinic waitlist without face-to-face consultation. Secondary outcomes: parent-reported severity of child sleep problems, clinic appointment need, child and parent psychosocial functioning, and health service use.
Methods: Parents of children aged 6 months to 12 years who were on the RCH Sleep Clinic waitlist were contacted to ascertain the nature of their child's sleep problem in March to August 2016. Children with possible behavioural sleep problems, no major developmental disability, and whose parents spoke English were invited to take part in the pilot randomised controlled trial (RCT). Eligible and consenting families were randomised to the targeted advice (TA, intervention, n=16) or the general advice (GA, control, n=17) group. TA families and referring clinicians received written and video resources tailored to the child's specific sleep problems. GA participants received information about the Raising Children Network website. Parents were surveyed two months post randomisation to assess outcomes.
Results: Thirty-three families (55% of those eligible) participated. 10/12 (83%) of the TA group would recommend the program to other parents. At follow up, fewer TA than GA parents still wanted a clinic appointment (9/15 (60%) vs 13/15 (87%) respectively), and fewer TA than GA parents reported their child's sleep as a moderate/severe problem (8/16 (50%) vs 12/15 (80%) respectively). Mean scores on the Child Sleep Habits Questionnaire were significantly better in the TA (52.4 (9.0)) versus GA (57.3 (6.7)) groups (adjusted mean difference -7.2, 95% CI -12.3 to -2.0, p=0.009). There were no significant changes in child and parent psychosocial outcomes.
Conclusion: The tailored "Sleep Help@Home" intervention appears acceptable to parents, and may reduce both sleep problems and clinic appointment need. This is the first such RCT of its kind. Results are informing a planned large RCT of an app based version of the intervention, which will be offered to parents of children on the hospital Sleep Clinic waiting list in 2018.
